Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan
暂无分享,去创建一个
K. Miyagawa | K. Tsuchihara | K. Oda | T. Ushiku | M. Kubo | H. Kenmotsu | M. Muto | H. Shirota | M. Tanabe | Y. Okuma | H. Kage | H. Hayashi | J. Kikuchi | A. Shinozaki-Ushiku | T. Kokuryo | D. Sakai | Akira Hirasawa | Y. Seto | Nana Akiyama | N. Okita
[1] H. Aburatani,et al. Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan , 2023, Cancer science.
[2] D. Ennishi,et al. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan , 2022, JAMA network open.
[3] K. Mertz,et al. How to read a next-generation sequencing report—what oncologists need to know , 2022, ESMO open.
[4] D. Ennishi,et al. Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors , 2022, Cancer science.
[5] K. Oda,et al. Current status and issues related to secondary findings in the first public insurance covered tumor genomic profiling in Japan: multi-site questionnaire survey , 2022, Journal of Human Genetics.
[6] M. Fassan,et al. The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. , 2021, Critical reviews in oncology/hematology.
[7] K. Ohe,et al. A clinical specific BERT developed using a huge Japanese clinical text corpus , 2021, PloS one.
[8] D. Ennishi,et al. Chronological improvement in precision oncology implementation in Japan , 2021, Cancer science.
[9] M. Takeda,et al. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy , 2021, Life.
[10] D. Ennishi,et al. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan , 2021, International Journal of Clinical Oncology.
[11] H. Ueno,et al. Establishment and implementation of Cancer Genomic Medicine in Japan , 2020, Cancer science.
[12] H. Aburatani,et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1) , 2020, International Journal of Clinical Oncology.
[13] A. Grothey,et al. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting , 2020, Journal of personalized medicine.
[14] H. Mano. Cancer genomic medicine in Japan , 2020, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[15] S. Fröhling,et al. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal , 2020, Nature Medicine.
[16] Claudio Luchini,et al. Molecular Tumor Boards in Clinical Practice. , 2020, Trends in cancer.
[17] A. Khorana,et al. Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study , 2020, JNCI cancer spectrum.
[18] M. McGowan,et al. Experiences of a Multidisciplinary Genomic Tumor Board Interpreting Risk for Underlying Germline Variants in Tumor-Only Sequencing Results. , 2019, JCO precision oncology.
[19] Akihiko Yoshida,et al. Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study , 2019, Cancer science.
[20] C. Swanton,et al. Prospective analysis of 895 patients on a UK Genomics Review Board , 2019, ESMO Open.
[21] R. Erlich,et al. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. , 2019, Journal of managed care & specialty pharmacy.
[22] O. Mariani,et al. Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie , 2018, ESMO Open.
[23] S. Sleijfer,et al. Molecular Tumor Boards: current practice and future needs , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Thomas S. Winokur,et al. Implementation and utilization of the molecular tumor board to guide precision medicine , 2017, Oncotarget.
[25] Gavin R. Oliver,et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery , 2017, Oncotarget.
[26] S. Lippman,et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. , 2014, The oncologist.